Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06515860 · ClinicalTrials.gov registry record
Neurofibromatosis Type 1 Tumor Early Detection Study
A clinical trial of Neurofibromatosis 1 and Neurofibromatosis Type 1, sponsored by David Miller.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06515860 is a study of Neurofibromatosis 1 and Neurofibromatosis Type 1 that is actively recruiting participants, run by David Miller. The registered enrollment target is 1,000 participants, roughly in line with the 994-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06515860, a study of Neurofibromatosis 1 and Neurofibromatosis Type 1, is actively recruiting participants, sponsored by David Miller.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to determine if a liquid biopsy (i.e. blood test) is an effective clinical tool for monitoring the development of malignant peripheral nerve sheath tumor (MPNST) among adults (18 years and older) with Neurofibromatosis Type 1 (NF1), compared to the current standard of care. The main questions it aims to answer are: How effective is liquid biopsy compared to the current standard of care (clinical surveillance and imaging) for early detection of MPNST development among people with NF1? Can liquid biopsy offer a cost-effective method for early detection of MPNST in people with NF1? Also, can liquid biopsy provide earlier detection that potentially leads to better outcomes? Also, can offering liquid biopsy improve access to care for people experiencing barriers to access (such as minority populations or people in rural areas)? At baseline, participants will be asked to: * Complete surveys to provide their demographic and NF1-related health information. * Report whether or not they are experiencing MPNST-related symptoms. * Provide blood samples (15 mL blood total between three tubes, which is approximately one tablespoon). Every six months during the five-year follow-up period, participants will be asked to: * Complete additional surveys to report whether or not they are experiencing MPNST-related symptoms and/or if they have been diagnosed with a new MPNST. * Provide an additional blood sample (10 mL blood total in one tube). If diagnosed with an MPNST by their healthcare provider during the follow-up period, participants will be asked to: * Complete an additional survey regarding their diagnosis and symptoms. * Provide an additional blood sample (10 mL blood in one tube). * In parallel, the study team will request a sample of tumor tissue from the care provider, if available.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Liquid biopsy for MPNST development
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2030-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06515860
The ClinicalTrials.gov registry entry for NCT06515860 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 994-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target. The listed sponsor is David Miller, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 1 intervention - of which Liquid biopsy for MPNST development is the first listed.
NCT06515860 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06515860 about?
NCT06515860 is a clinical study titled "Neurofibromatosis Type 1 Tumor Early Detection Study". The goal of this observational study is to determine if a liquid biopsy (i.e. blood test) is an effective clinical tool for monitoring the development of malignant peripheral nerve sheath tumor (MPNST) among adults (18 years and older) with Neurofibromatosis Type 1 (NF1), compared to the current sta...
What is the current status of trial NCT06515860?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-08-07. Estimated completion is 2030-07.
What conditions does trial NCT06515860 study?
This clinical trial studies the following conditions: Neurofibromatosis 1, Neurofibromatosis Type 1, Plexiform Neurofibroma, Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumor.
What interventions are being tested in trial NCT06515860?
The interventions under investigation include: Liquid biopsy for MPNST development (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06515860?
This trial is sponsored by David Miller, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06515860 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.